Price Target N/A Consensus Rating N/A Company Overview Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase ...
DESTINY PHARMA PLC ORD GBP0.01(DEST)股吧,股民朋友可以在这里畅所欲言,分析讨论股票名的最新动态。东方财富股吧,专业的股票论坛社区。
picks analysis by sector energy communication services real estate consumer staples tech basic materials healthcare consumer utilities financials industrials stock comparison tools faang stocks gold etfs cash equivalents big bank stocks big pharma stocks retail stocks top indexes dow jones s&p 500 nasdaq g...
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are publishe...